Previous 10 | Next 10 |
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
It looks like Santa rally may finally come to the US Stock Market. Let’s take a look at some of the hot stocks on the big boards today. Shares of 22nd Century Group, Inc. (NASDAQ: XXII) gained $0.85 after the company announced that the U.S. Food and Drug Administration (FDA) has author...
Gainers: Zhangmen Education (NYSE:ZME) +474%. 22nd Century Group (NASDAQ:XXII) +49%. Pasithea Therapeutics (NASDAQ:KTTA) +36%. Theseus Pharmaceuticals (NASDAQ:THRX) +32%. Qualigen Therapeutics (NASDAQ:QLGN) +32%. Allakos (NASDAQ:ALLK) +27%. REE Automotive (NASDAQ:REE) +26%. View (NASDAQ:VIEW)...
Lirentelimab's phase 3 failures are spectacular considering the excellent phase 2 data. No one has yet figured out how this went down. However, from every angle, the future of the company looks bleak. For further details see: Allakos: Sad End To A Promising Asset
Pasithea Therapeutics (NASDAQ:KTTA) 31%. Ensysce Biosciences (NASDAQ:ENSC) +23%. Turkcell Iletisim Hizmetleri (NYSE:TKC) +16%. Kaixin Auto (NASDAQ:KXIN) +13% after enters framework pact for order of 10,000 electric trucks. Allakos (NASDAQ:ALLK) +11% amid bea...
After losing more than a quarter of its market cap on Wednesday, Allakos (NASDAQ:ALLK) shares have recovered in the pre-market with a rise of ~10.9% on above-average volume. About 4.6M company shares have changed hands compared to the 65-day average volume of ~1.3M. According to sit...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! Christmas is almost here but were aren’t slowing down as we dive into the biggest pre-market stock movers for Thursday! Source: Shutterstock Stories moving stocks this morning include re...
Stocks advanced on Wednesday, continuing the choppy action that has dominated the past month or so, as Wall Street looks content to tread water as the Christmas holiday approaches. The homebuilding sector acted as a microcosm of this action. The group posted gains on Tuesday and Wednesday, pa...
Allakos Inc ( NASDAQ: ALLK ) announced its results from Enigma II, Phase III placebo-controlled, double-blind clinical research of lirentelimab on people battling EG (eosinophilic gastritis) and went up by around 80%. The company also concluded its Kryptos study of liren...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Since the rise of the omicron variant, the biotech and pharmaceutical sectors have been in the spotlight. While we’ve seen some companies with plenty to celebrate, not everyone has been so lucky. One company in parti...
News, Short Squeeze, Breakout and More Instantly...
– AK006 achieved serum concentrations consistent with levels demonstrating inhibitory activity in preclinical experiments – – Skin biopsies from subjects treated with AK006 show high receptor occupancy – – AK006 was well-tolerated with a favorable safety pro...
– Top-line Phase 1 CSU results expected at year end 2024 – SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK006 for the treatment of mast cell-driven diseases, today announced that the first patient with chr...
SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for...